Proven medicines.
Delivered faster.

Algorae Pharmaceuticals (ASX: 1AI) is an Australian pharmaceutical company operating at the intersection of commercial supply and R&D.

AlgoraeRx sources and supplies generic and specialty medicines to the Australian market through partnerships with leading global manufacturers. AlgoraeOS, our AI-powered drug discovery platform, accelerates the development of our long-term pipeline.

Explore AlgoraeRx

Explore AlgoraeOS

Investor Centre

Algorae Pharmaceuticals Limited (ASX: 1AI)

is an Australian pharmaceutical company operating at the intersection of commercial supply and R&D. We source, register, and supply generic and specialty medicines to the Australian and New Zealand markets through executed supply and licensing agreements with Tier-1 global manufacturers — while developing our long-term proprietary pipeline through AlgoraeOS, our AI-powered drug discovery platform.

AlgoraeRx is our primary commercial focus. The business is led by a team with direct experience scaling pharmaceutical distribution at an institutional level across Australia and New Zealand.

AlgoraeOS, our proprietary AI-powered drug discovery platform, is built in partnership with UNSW AI Institute and CSIRO Data 61, with independent validation from the Peter MacCallum Cancer Centre. The platform generates high-confidence drug-combination candidates for licensing and co-development.

Algorae is listed on the Australian Securities Exchange (ASX: 1AI).

Division Overview

AlgoraeRx is our primary commercial focus. AlgoraeOS is our AI-powered drug discovery platform, developing the long-term pipeline.

AlgoraeRx — COMMERCIAL DIVISION

Supplying Generic & Specialty Medicines to the Australian and New Zealand Markets.

AlgoraeRx operates a Source–Register–Supply model. We identify generic and specialty medicines to address unmet medical needs, secure license and supply agreements with Tier-1 global manufacturers, obtain TGA regulatory approvals, and supply to institutional markets across Australia and New Zealand.

Learn More About AlgoraeRx

AlgoraeOS — DISCOVERY PLATFORM

AI-Powered Drug Discovery,
Independently Validated.

AlgoraeOS is our AI-powered drug discovery platform, developed in collaboration with UNSW AI Institute and CSIRO Data 61, and independently validated at the Peter MacCallum Cancer Centre. The platform generates high-confidence drug-combination candidates across complex disease areas, providing Algorae with a continuously developing pipeline of novel programs for licensing and co-development.

Learn More About AlgoraeOS

3

Supply agreements executed with Tier-1 manufacturers

$3M

Non-dilutive receivables facility

90

AI-validated drug candidates

Why Algorae

Most pharmaceutical companies ask investors to wait a decade and spend hundreds of millions before seeing a return. Algorae is built differently.

Contracted. Not Speculative.

We hold executed supply agreements with three Tier-1 manufacturers operating in highly regulated global markets – commercialising products through signed agreements.

Efficient Capital. Shareholder-Friendly.

Working capital is deployed into TGA registration and distribution. Our financing structure funds execution and revenue with minimal shareholder dilution, delivering a fundamentally different risk-return profile to traditional biotech.

Validated Platform. Pipeline Upside.

AlgoraeOS is independently validated at the Peter MacCallum Cancer Centre. Our AI-powered drug discovery platform delivers pipeline upside on top of a revenue-generating commercial business.

Australia has a medicine supply problem. AlgoraeRx is working to solve it.

The Australian pharmaceutical market is large and growing, yet supply is dominated by multinationals with no structural incentive to prioritise Australian patients. TGA-registered medication shortages are a recurring problem — not a temporary disruption.

AlgoraeRx’s Source–Register–Supply model is purpose-built to move faster than multinational incumbents that currently dominate distribution. Every product we bring to market is a medicine that an Australian patient needed and couldn’t get.